Prostate cancer: local control and radiotherapy matter in prostate cancer.
In a study published in The Lancet, long-term androgen suppression (AS) combined with radiotherapy, compared with AS alone, improved outcomes in patients with locally advanced but nonmetastatic prostate cancer. The combined therapy significantly reduced prostate-cancer-specific deaths at 10 years from 23.9% to 11.9% (P <0.001), and improved overall survival.
Seth A
SA
Rosenthal
D000726:Androgen Antagonists / Q000627:therapeutic use; D003131:Combined Modality Therapy; D006801:Humans; D008297:Male; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000532:radiotherapy*; D016032:Randomized Controlled Trials as Topic / Q000379:methods
D000726:Androgen Antagonists